In a development that’s sure to cheer the pharmaceutical industry, the U.S. Supreme Court declined on Monday to review a lower court ruling limiting drug companies’ False Claims Act liability for shoddy distribution practices.
The justices denied a bid by whistleblower Barry Rostholder to revive claims that his former employer, Omnicare Inc., defrauded Medicare and Medicaid by distributing contaminated penicillin. The U.S. Court of Appeals for the Fourth Circuit ruled earlier this year that even if Rostholder’s contamination claims are true, the False Claims Act doesn’t cover Omnicare’s alleged misconduct.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
